0001567619-23-000460.txt : 20230105
0001567619-23-000460.hdr.sgml : 20230105
20230105162908
ACCESSION NUMBER: 0001567619-23-000460
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230103
FILED AS OF DATE: 20230105
DATE AS OF CHANGE: 20230105
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Eichorn Laura G.
CENTRAL INDEX KEY: 0001861067
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40604
FILM NUMBER: 23511710
MAIL ADDRESS:
STREET 1: IMAGO BIOSCIENCES, INC.
STREET 2: 329 OYSTER POINT BLVD. 3RD FL
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Imago BioSciences, Inc.
CENTRAL INDEX KEY: 0001623715
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 454915810
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 303 TWIN DOLPHIN DRIVE
STREET 2: 6TH FLOOR
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
BUSINESS PHONE: (415) 529-5055
MAIL ADDRESS:
STREET 1: 303 TWIN DOLPHIN DRIVE
STREET 2: 6TH FLOOR
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
4
1
doc1.xml
FORM 4
X0306
4
2023-01-03
0
0001623715
Imago BioSciences, Inc.
IMGO
0001861067
Eichorn Laura G.
C/O IMAGO BIOSCIENCES, INC.
303 TWIN DOLPHIN DRIVE, 6TH FLOOR
REDWOOD CITY
CA
94065
0
1
0
0
Chief Financial Officer
Common Stock
2023-01-03
4
M
0
22950
2.52
A
232284
D
Common Stock
2023-01-03
4
M
0
12400
4.2
A
244684
D
Common Stock
2023-01-03
4
M
0
1769
22.76
A
246453
D
Stock Option (Right to Buy)
2.52
2023-01-03
4
M
0
22950
0
D
2021-01-01
2027-03-28
Common Stock
22950
0
D
Stock Option (Right to Buy)
4.2
2023-01-03
4
M
0
12400
0
D
2031-02-04
Common Stock
12400
11409
D
Stock Option (Right to Buy)
22.76
2023-01-03
4
M
0
1769
0
D
2031-11-16
Common Stock
1769
101231
D
Reflects the adjusted total which includes the purchase of 1,597 shares under the Imago Employee Stock Purchase Plan on November 30, 2022.
One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from November 12, 2020 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
25% of the shares subject to the option vest on the first anniversary measured from November 17, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
/s/ Hugh Rienhoff, as Attorney-in-fact for Laura Eichorn
2023-01-05